Abstract
Gene therapies offer great promise for the future of medicine, with adeno-associated viral (AAV) vectors emerging as one of the leading delivery vehicles for these innovative therapies. However, the production of AAV-based therapies using HEK293 cells is a complicated process. Regulatory agencies have created expedited approval pathways for these promising, but complex, therapeutics. However, developers face important time constraints in developing robust manufacturing workflows. For these reasons, a successful chemicals, manufacturing, and control (CMC) strategy must be established as soon as possible to prevent delays during clinical trials. To support the implementation of this strategy, AAV manufacturers are looking for solutions to accelerate process and analytical development, notably those that can help with the selection and optimization of a suitable cell culture medium. The Gibco™ Viral Vector HEK Media Panel is the first panel solution for gene therapy manufacturers, and it has the potential to accelerate media optimization. The following article describes how the media panel can be used to quickly identify media candidates for multiple HEK293 cell lineages.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
